CDMO Bespak and DevPro Biopharma have revealed their partnership on development of DevPro’s DP007 albuterol MDI, which is formulated with Honeywell’s Solstice Air HFO-1234ze(E) propellant. According to the companies, DP007 is expected to provide a lower global warming potential alternative to Ventolin HFA MDI. Bespak and DevPro say that they plan to initiate clinical trials by the end of 2024 with a goal of commercialization in mid-2027, and DevPro is currently looking for a partner to support continued development of the MDI.
Bespak, which recently spun out from Recipharm, has previously announced partnerships related to the transition to low global warming potential (LGWP) propellants with H&T Presspart and with Honeywell. The work on DP007 is being performed at Bespak’s research facility in North Carolina.
DevPro Biopharma CEO Colin Reisner commented, “Albuterol pMDIs account for approximately 45% of all pMDIs used worldwide, contributing substantially to global warming. . . . There is an urgent need to develop a low-GWP albuterol pMDI to reduce the environmental impact of the life-saving inhalers patients need, without sacrificing performance or ease-of-use. Working with Bespak, we are excited about the results we have seen with DP007 showing comparable performance with Ventolin HFA.”
Bespak CEO Chris Hirst said, “We’re committed to leading the transition to low-GWP propellants in pMDIs to help halt the global warming caused by greenhouse gases. Bespak has a long history in the development, scale-up, and clinical and commercial supply of inhalers and our goal now is to transition as many pMDI products as possible to meet the requirements of evolving global legislation. We believe in not only leveraging our own skills and capabilities, including our expertise in valves, actuators, and dose counters, but also working together across the industry to achieve this goal. Building on our partnership with Honeywell, we are proud to partner with the experienced team at DevPro Biopharma on this exciting development.”
Read the Bespak press release.
